Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16046067 | 0.86 | PDE2A (0.47) | MAOAMAOBPDK2GPR88IDH1 | |
| SCHEMBL19876584 | 0.86 | PDE2A (0.47) | MAOAMAOBPDK2GPR88IDH1 | |
| SCHEMBL17658878 | 0.86 | MAOA (0.41) | MAOAMAOBPDK2CARM1KMT2A | |
| SCHEMBL18119645 | 0.85 | NQO1 (0.48) | CARM1KMT2AMAPTHPGDPDE2A | |
| SCHEMBL16997126 | 0.83 | TDP1 (0.50) | PDK2CARM1KMT2AL3MBTL1LMNA | |
| SCHEMBL15000540 | 0.81 | CARM1 (0.49) | CARM1KMT2AL3MBTL1LMNAPDE2A | |
| SCHEMBL22857118 | 0.81 | CARM1 (0.46) | MAOBPDK2CARM1KMT2ALMNA | |
| SCHEMBL19618909 | 0.81 | CARM1 (0.52) | PDK2CARM1KMT2AL3MBTL1LMNA | |
| SCHEMBL8137382 | 0.81 | CARM1 (0.39) | MAOAMAOBCARM1GPR88KMT2A | |
| SCHEMBL14363223 | 0.80 | FFAR1 (0.45) | MAOAMAOBPDK2CARM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882863-B2 | Compounds for reducing c-Myc in c-Myc overexpressing cancers background | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190194212-A1 | Compounds For Reducing c-Myc In c-Myc Overexpressing Cancers Background | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-06-27 | — | — | US | disclosed |
| US-20190070183-A1 | Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases | UNIV COLUMBIA (US) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194212-A1 | Compounds For Reducing c-Myc In c-Myc Overexpressing Cancers Background | MYC, MYCBP, BCOR | MAOA 3542/4885MAOB 3265/4885PDK2 1477/4885 |
| US-20190070183-A1 | Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases | MYC, MTOR, MALT1 | MAOA 4774/4885MAOB 4763/4885PDK2 1985/4885 |
| US-10882863-B2 | Compounds for reducing c-Myc in c-Myc overexpressing cancers background | MYC, MYCBP, BCOR | MAOA 3668/4885MAOB 3372/4885PDK2 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.